
Understand the normal cell cycle and its control mechanisms, then explore cancer development and monoclonal antibodies, including hybridoma production and antibody therapies.
G1-CDK frees E2F from Rb, boosting cyclin E and activating G1-S CDK to prepare origins for firing. S-CDK (cyclin A–CDK2) ensures DNA replication proceeds properly and happens once per cycle.
Explore the metaphase stage of the M phase, detailing bipolar attachment of sister chromatids via kinetochore microtubules and the spindle assembly checkpoint that halts anaphase until proper attachment.
Examine how the spindle assembly checkpoint ensures bipolar attachment and metaphase arrest, via MAD-1 and MAD-2 activating C-MAD-2 to inhibit CDC-20 and the anaphase promoting complex, preventing aneuploidy.
Explore how the ubiquitin proteasome system maintains protein homeostasis and cell-cycle control through ubiquitination, polyubiquitination, and degradation by the 26 proteasome.
Define cancer as abnormal, uncoordinated cell division forming neoplasms, differentiate benign and malignant tumors by parenchyma and stroma, and explain nomenclature such as adenoma, fibroma, chondroma, osteoma, papilloma.
Explain how malignant tumors use sarcoma and carcinoma suffixes to reflect mesenchymal or epithelial origin, contrasting with benign neoplasms like fibroma and adenoma.
Investigate the molecular basis of cancer by studying proto oncogenes, oncogenes, and tumor suppressor genes, including Cyclin D1–CDK4/6 signaling, p53, and translocations like Burkitt's lymphoma and Philadelphia chromosome.
Discover the antibody structure, including light and heavy chains with variable and constant domains, fab and fc regions, and the role of CDRs and somatic recombination in antigen recognition.
Course Description: Oncology and Monoclonal Antibodies
Course Overview
This course will focus on the fascinating mechanisms of the normal cell cycle, explaining how it functions under typical conditions. You’ll also learn what happens when the regulatory controls of the cell cycle break down, leading to the development of cancer. Additionally, we will explore the cutting-edge world of monoclonal antibodies and how they can be used as a powerful treatment for cancer. This comprehensive course designed for students and professionals alike with the following details of the contents of the course.
The Cell Cycle
Explore the different phases of the cell cycle and the machinery (centrosomes, kinetochores and microtubules) that ensures proper cell division.
Understand the pivotal roles of the control system of the cell cycle that includes cyclins, cyclin-dependent kinases and the regulated destruction machinery (Ubiquitin Proteasome System)
The Role of p53
Discover how the p53 protein serves as a guardian of the genome, and how it make sure that the daughters cells will receive an intact copy of the genetic material by stopping the cell cycle when there is damage to the DNA.
Cancer Basics
Basics of the Neoplasm/tumor and the nomenclature and classification of the tumor.
What are the differences between benign and malignant tumors.
Carcinogenesis
What are the roles of carcinogens and co-carcinogens in cancer development.
Understand the differences in protooncogenes, oncogenes, and tumor suppressor genes and how they work.
Normal vs. Cancer Cells
Understand the fundamental differences between normal and cancer cells.
The students will explore the cancer staging system (The TNM system and the numbering system)
Monoclonal Antibodies and Cancer Treatment
The Structure of the Antibody; Heavy and Light Chains, Hinge Region, CDR
The B-cell Receptor and the Secretory Antibodies and their Differences
What are monoclonal antibodies and their characteristics
How the monoclonal antibodies are produced by the hybridoma technology
How to select the desired hybridoma, from the mixture of hybridoma, using HAT media.
How to screen the hybridoma for their desired functions using different techniques like ELISA and affinity chromatography
Discover the various types of monoclonal antibodies used for the treatment of cancer; naked, conjugated and bispecific and the use of different monoclonal antibodies like Alemtuzumab, Brentuximab vedotin